Copyright Reports & Markets. All rights reserved.

Global Bio Similars/Subsequent Entry Biologic Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Bio Similars/Subsequent Entry Biologic Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Monoclonal Antibodies
      • 1.4.3 Interferon
      • 1.4.4 Erythropoietin
      • 1.4.5 Insulin
      • 1.4.6 Vaccines
      • 1.4.7 Other
    • 1.5 Market by Application
      • 1.5.1 Global Bio Similars/Subsequent Entry Biologic Market Share by Application (2014-2025)
      • 1.5.2 Tumor
      • 1.5.3 Diabetes
      • 1.5.4 Cardiovascular
      • 1.5.5 Hemophilia
      • 1.5.6 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Bio Similars/Subsequent Entry Biologic Market Size
    • 2.2 Bio Similars/Subsequent Entry Biologic Growth Trends by Regions
      • 2.2.1 Bio Similars/Subsequent Entry Biologic Market Size by Regions (2014-2025)
      • 2.2.2 Bio Similars/Subsequent Entry Biologic Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Bio Similars/Subsequent Entry Biologic Market Size by by Players
      • 3.1.1 Global Bio Similars/Subsequent Entry Biologic Revenue by by Players (2014-2019)
      • 3.1.2 Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Bio Similars/Subsequent Entry Biologic Market Concentration Ratio (CR5 and HHI)
    • 3.2 Bio Similars/Subsequent Entry Biologic Key Players Head office and Area Served
    • 3.3 Key Players Bio Similars/Subsequent Entry Biologic Product/Solution/Service
    • 3.4 Date of Enter into Bio Similars/Subsequent Entry Biologic Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Bio Similars/Subsequent Entry Biologic Market Size by Type (2014-2019)
    • 4.2 Global Bio Similars/Subsequent Entry Biologic Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Bio Similars/Subsequent Entry Biologic Market Size (2014-2019)
    • 5.2 Bio Similars/Subsequent Entry Biologic Key Players in United States
    • 5.3 United States Bio Similars/Subsequent Entry Biologic Market Size by Type
    • 5.4 United States Bio Similars/Subsequent Entry Biologic Market Size by Application

    6 Europe

    • 6.1 Europe Bio Similars/Subsequent Entry Biologic Market Size (2014-2019)
    • 6.2 Bio Similars/Subsequent Entry Biologic Key Players in Europe
    • 6.3 Europe Bio Similars/Subsequent Entry Biologic Market Size by Type
    • 6.4 Europe Bio Similars/Subsequent Entry Biologic Market Size by Application

    7 China

    • 7.1 China Bio Similars/Subsequent Entry Biologic Market Size (2014-2019)
    • 7.2 Bio Similars/Subsequent Entry Biologic Key Players in China
    • 7.3 China Bio Similars/Subsequent Entry Biologic Market Size by Type
    • 7.4 China Bio Similars/Subsequent Entry Biologic Market Size by Application

    8 Japan

    • 8.1 Japan Bio Similars/Subsequent Entry Biologic Market Size (2014-2019)
    • 8.2 Bio Similars/Subsequent Entry Biologic Key Players in Japan
    • 8.3 Japan Bio Similars/Subsequent Entry Biologic Market Size by Type
    • 8.4 Japan Bio Similars/Subsequent Entry Biologic Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size (2014-2019)
    • 9.2 Bio Similars/Subsequent Entry Biologic Key Players in Southeast Asia
    • 9.3 Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size by Type
    • 9.4 Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size by Application

    10 India

    • 10.1 India Bio Similars/Subsequent Entry Biologic Market Size (2014-2019)
    • 10.2 Bio Similars/Subsequent Entry Biologic Key Players in India
    • 10.3 India Bio Similars/Subsequent Entry Biologic Market Size by Type
    • 10.4 India Bio Similars/Subsequent Entry Biologic Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Bio Similars/Subsequent Entry Biologic Market Size (2014-2019)
    • 11.2 Bio Similars/Subsequent Entry Biologic Key Players in Central & South America
    • 11.3 Central & South America Bio Similars/Subsequent Entry Biologic Market Size by Type
    • 11.4 Central & South America Bio Similars/Subsequent Entry Biologic Market Size by Application

    12 International Players Profiles

    • 12.1 Sun Pharma
      • 12.1.1 Sun Pharma Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Bio Similars/Subsequent Entry Biologic Introduction
      • 12.1.4 Sun Pharma Revenue in Bio Similars/Subsequent Entry Biologic Business (2014-2019)
      • 12.1.5 Sun Pharma Recent Development
    • 12.2 Synthon Pharmaceuticals
      • 12.2.1 Synthon Pharmaceuticals Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Bio Similars/Subsequent Entry Biologic Introduction
      • 12.2.4 Synthon Pharmaceuticals Revenue in Bio Similars/Subsequent Entry Biologic Business (2014-2019)
      • 12.2.5 Synthon Pharmaceuticals Recent Development
    • 12.3 Teva Pharmaceutical Industries
      • 12.3.1 Teva Pharmaceutical Industries Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Bio Similars/Subsequent Entry Biologic Introduction
      • 12.3.4 Teva Pharmaceutical Industries Revenue in Bio Similars/Subsequent Entry Biologic Business (2014-2019)
      • 12.3.5 Teva Pharmaceutical Industries Recent Development
    • 12.4 LG Life Sciences
      • 12.4.1 LG Life Sciences Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Bio Similars/Subsequent Entry Biologic Introduction
      • 12.4.4 LG Life Sciences Revenue in Bio Similars/Subsequent Entry Biologic Business (2014-2019)
      • 12.4.5 LG Life Sciences Recent Development
    • 12.5 Celltrion Biocon
      • 12.5.1 Celltrion Biocon Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Bio Similars/Subsequent Entry Biologic Introduction
      • 12.5.4 Celltrion Biocon Revenue in Bio Similars/Subsequent Entry Biologic Business (2014-2019)
      • 12.5.5 Celltrion Biocon Recent Development
    • 12.6 Hospira
      • 12.6.1 Hospira Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Bio Similars/Subsequent Entry Biologic Introduction
      • 12.6.4 Hospira Revenue in Bio Similars/Subsequent Entry Biologic Business (2014-2019)
      • 12.6.5 Hospira Recent Development
    • 12.7 Merck
      • 12.7.1 Merck Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Bio Similars/Subsequent Entry Biologic Introduction
      • 12.7.4 Merck Revenue in Bio Similars/Subsequent Entry Biologic Business (2014-2019)
      • 12.7.5 Merck Recent Development
    • 12.8 Biogen idec
      • 12.8.1 Biogen idec Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Bio Similars/Subsequent Entry Biologic Introduction
      • 12.8.4 Biogen idec Revenue in Bio Similars/Subsequent Entry Biologic Business (2014-2019)
      • 12.8.5 Biogen idec Recent Development
    • 12.9 Genentech (Roche)
      • 12.9.1 Genentech (Roche) Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Bio Similars/Subsequent Entry Biologic Introduction
      • 12.9.4 Genentech (Roche) Revenue in Bio Similars/Subsequent Entry Biologic Business (2014-2019)
      • 12.9.5 Genentech (Roche) Recent Development
    • 12.10 Pfizer
      • 12.10.1 Pfizer Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Bio Similars/Subsequent Entry Biologic Introduction
      • 12.10.4 Pfizer Revenue in Bio Similars/Subsequent Entry Biologic Business (2014-2019)
      • 12.10.5 Pfizer Recent Development
    • 12.11 Celltrion
    • 12.12 Biocon
    • 12.13 Amgen
    • 12.14 Samsung Biologics
    • 12.15 Mylan
    • 12.16 Dr. Reddy's Laboratories
    • 12.17 Stada Arzneimittel AG
    • 12.18 AbbVie
    • 12.19 Sanofi-Aventis
    • 12.20 Johnson & Johnson
    • 12.21 Novo Nordisk
    • 12.22 Eli Lilly
    • 12.23 Novartis
    • 12.24 3sbio
    • 12.25 Biotech
    • 12.26 Gelgen
    • 12.27 Innovent
    • 12.28 Dong Bao
    • 12.29 Ganlee

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global Bio Similars/Subsequent Entry Biologic market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Bio Similars/Subsequent Entry Biologic status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Bio Similars/Subsequent Entry Biologic development in United States, Europe and China.

      The key players covered in this study
      Sun Pharma
      Synthon Pharmaceuticals
      Teva Pharmaceutical Industries
      LG Life Sciences
      Celltrion Biocon
      Hospira
      Merck
      Biogen idec
      Genentech (Roche)
      Pfizer
      Celltrion
      Biocon
      Amgen
      Samsung Biologics
      Mylan
      Dr. Reddy's Laboratories
      Stada Arzneimittel AG
      AbbVie
      Sanofi-Aventis
      Johnson & Johnson
      Novo Nordisk
      Eli Lilly
      Novartis
      3sbio
      Biotech
      Gelgen
      Innovent
      Dong Bao
      Ganlee

      Market segment by Type, the product can be split into
      Monoclonal Antibodies
      Interferon
      Erythropoietin
      Insulin
      Vaccines
      Other

      Market segment by Application, split into
      Tumor
      Diabetes
      Cardiovascular
      Hemophilia
      Other

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Bio Similars/Subsequent Entry Biologic status, future forecast, growth opportunity, key market and key players.
      To present the Bio Similars/Subsequent Entry Biologic development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Bio Similars/Subsequent Entry Biologic are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now